prof Analysis of CXCL12 and S100A12 levels in peripheral blood and synovial fluid and their correlation with severity in patients with knee osteoarthritis:

Yili Ye

doi:10.5937/jomb0-46310

Yili Ye Taizhou Traditional Chinese Medicine Hospital (Currently in the Logistics Support Department), Taizhou, 317700, Zhejiang Province, China

DOI: https://doi.org/10.5937/jomb0-46310

Keywords: knee osteoarthritis, CXCL12, S100A12, correlation

Abstract

Abstract: To investigate the expression of CXCL12 and S100A12 in peripheral blood (PB) and synovial fluid (SF) of patients with knee osteoarthritis (OS) and to analyze the correlation between them and the severity of knee OS. 60 patients with kneeOS treated in our hospital from January 2020 to December 2022 were selected as the experimental group, and 60 healthy knee joints with similar age were selected as the control group. The fasting venous blood of 120 subjects was drawn in the early morning, and the SF was extracted during joint operation or sodium hyaluronate injection. Put the collected PB and SF in the refrigerator at-80℃. The levels of CXCL12 and S100A12 in PB and SF were detected by enzyme linked immunosorbent assay (Elisa). The correlation between the levels of CXCL12 and S100A12 in PB and SF and Kmurl L grade and WOMAC score. The levels of CXCL12 and S100A12 in PB and SF in the observation group were raised than those in the control group. There were significant differences in the levels of CXCL12 and S100A12 in PB and SF in the experimental group. The higher the Kmurl grade of knee OS, the higher the concentration of CXCL12 and S100A12 in PB and SF. The levels of CXCL12 and S100A12 in PB of knee OS were positively correlated with WOMAC score (r = 0.767, 0.521 respectively, P < 0.05), see figure 1. The levels of CXCL12 and S100A12 in SF of knee OS were positively correlated with WOMAC score (r = 0.663, 0.357 respectively, P < 0.05). The levels of CXCL12 and S100A12 in PB and SF are positively correlated with the severity of knee OS. The levels of CXCL12 and S100A12 in PB and SF can provide basis for the evaluation and prognosis of knee OS.

References

1. Bennell KL, Paterson KL, Metcalf BR, Duong V, Eyles J, Kasza J, Wang Y, Cicuttini F, Buchbinder R, Forbes A, Harris A, Yu SP, Connell D, Linklater J, Wang BH, Oo WM, Hunter DJ. Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: the RESTORE randomized clinical trial. JAMA, 2021;326(20):2021-2030.

2. Rezuş E, Burlui A, Cardoneanu A, Macovei LA, Tamba BI, Rezuş C. From pathogenesis to therapy in knee osteoarthritis: bench-to-bedside. Int J Mol Sci, 2021;22(5):2697(1-24).

3. Øiestad BE, Juhl CB, Eitzen I, Thorlund JB. Knee extensor muscle weakness is a risk factor for development of knee osteoarthritis. A systematic review and meta-analysis. Osteoarthritis Cartilage, 2015;23(2):171-177.

4. He W, Wang M, Wang Y, Wang Q, Luo B. Plasma and synovial fluid CXCL12 levels are correlated with disease severity in patients with knee osteoarthritis. J Arthroplasty, 2016;31(2):373-377.

5. Xu Q, Sun XC, Shang XP, Jiang HS. Association of CXCL12 levels in synovial fluid with the radiographic severity of knee osteoarthritis. J Investig Med, 2012;60(6):898-901.

6. Wang LC, Zhang HY, Shao L, Chen L, Liu ZH, He X, Gong WX. S100A12 levels in synovial fluid may reflect clinical severity in patients with primary knee osteoarthritis. Biomarkers, 2013;18(3):216-20.

7. Raeissadat SA, Rayegani SM, Hassanabadi H, Fathi M, Ghorbani E, Babaee M, Azma K. Knee osteoarthritis injection choices: Platelet-Rich Plasma (PRP) versus hyaluronic acid (A one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord, 2015;8(8):1-8.

8. Kasemsuk T, Saengpetch N, Sibmooh N, Unchern S. Improved WOMAC score following 16-week treatment with bromelain for knee osteoarthritis. Clin Rheumatol, 2016;35(10):2531-40.

9. Kang BX, Ma J, Shen J, Xu H, Wang HQ, Zhao C, Xie J, Zhong S, Gao CX, Xu XR, A XY, Gu XL, Xiao L, Xu J. Altered brain activity in end-stage knee osteoarthritis revealed by resting-state functional magnetic resonance imaging. Brain Behav, 2022;12(1):e2479(1-9).

10. Sukerkar PA, Doyle Z. Imaging of osteoarthritis of the knee. Radiol Clin North Am, 2022;60(4):605-616.

11. Ahmed U, Anwar A, Savage RS, Thornalley PJ, Rabbani N. Protein oxidation, nitration and glycation biomarkers for early-stage diagnosis of osteoarthritis of the knee and typing and progression of arthritic disease. Arthritis Res Ther, 2016;18(1):250(1-11).

12. Daniel SK, Seo YD, Pillarisetty VG. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Semin Cancer Biol, 2020;65:176-188.

13. Kim SK, Choe JY, Park KY. CXCL12 and CXCR4 as Novel Biomarkers in Uric Acid-Induced Inflammation and Patients with Gouty Arthritis. Biomedicines, 2023;11(3):649 (1-12).

14. Nakashima M, Sakai T, Hiraiwa H, Hamada T, Omachi T, Ono Y, Inukai N, Ishizuka S, Matsukawa T, Oda T, Takamatsu A, Yamashita S, Ishiguro N. Role of S100A12 in the pathogenesis of osteoarthritis. Biochem Biophys Res Commun, 2012;422(3):508-14.

15. Lin ST. Role of serum S100A12 in diagnosis and evaluation of ulcerative colitis. World Chin J Digestology, 2016;24(7):1103-1106.

16. Lu W, Shi J, Zhang J, Lv Z, Guo F, Huang H, Zhu W, Chen A. CXCL12/CXCR4 axis regulates aggrecanase activation and cartilage degradation in a post-traumatic osteoarthritis rat model. Int J Mol Sci, 2016;17(10):1522(1-16).